An Industry Innovator
With our innovative and cutting edge technologies, our primary objective is to improve patient outcomes. Founded in 2015, our incredible team of scientists have worked tirelessly to take NanoTomer, Inc. to the forefront of targeted oncology companies.
In order to be a leader in targeted oncology, we have dedicated time and resources, in collaboration with our partners at Massachusetts General Hospital and Brigham and Women's Hospital, to develop therapies that address unmet needs in the oncology space.
We continue to work tirelessly to become the technological standard in antibody/protein drug conjugates, providing big picture insights which industry leaders not only approve of, but also depend on. Get in touch to learn more.
Antibody Drug Conjugate
MHA112 is our proprietary antibody developed to seek out cancer in the body. By linking MHA112 to powerful drug conjugates, we will enable the targeted delivery of highly potent active pharmaceuticals directly to primary tumors and metastatic sites concurrently.
Peptide Drug Conjugate
Protin101 is a proprietary peptide that acts as the basis for several drug conjugates developed for targeted delivery of pharmaceutical payloads or the endogenous activation of T-cells. Targeted payloads being developed include highly potent pharmaceuticals and checkpoint inhibitors.
Protin101 has potential uses in cancer therapy, treatment of auto immune diseases such as IBD, and CAR-T therapy.
News & Updates
From new version releases to exciting news related to fundraising, we want our followers to stay in the loop when it comes to NanoTomer, Inc.. Read our updates below to find out what we’ve been up to recently, and if you have any questions at all, don’t hesitate to get in touch. We’re always happy to hear from our supporters.
As we achieve newsworthy events and milestones we will publish articles here. In the meantime please don't hesitate to contact us for more information.